Flexible dosing to help meet the individual needs of your patients

Select condition:

AUSTEDO (deutetrabenazine) tablets offers the most FDA-approved dosing options to help meet the needs of a diverse tardive dyskinesia (TD) patient population.1,2

Dial representing multiple dosing options that can range from 24mg/day to 48mg/day.
AUSTEDO is available in 6 mg, 9 mg, and 12 mg tablets and can help provide TD symptom control across a range of therapeutic doses.1
6mg AUSTEDO® (deutetrabenazine) tablets
9mg AUSTEDO® (deutetrabenazine) tablets
12mg AUSTEDO® (deutetrabenazine) tablets
Multiple therapeutic dosing options range from 24 mg/day to 48 mg/day.1

Weekly titration allows for flexible dosing of AUSTEDO tablets1

Week
Strength/Quantity of AUSTEDO
Total Daily Dosage
1
6 mg BID (QTY #14)
12 mg
2
9 mg BID (QTY #14)
18 mg
3
12 mg BID (QTY #14)
24 mg
4
6 mg BID (QTY #14)
+9 mg BID (QTY #14)
30 mg
5
9 mg BID (QTY #14)
+9 mg BID (QTY #14)
36 mg
6
9 mg BID (QTY #14)
+12 mg BID (QTY #14)
42 mg
7
12 mg BID (QTY #14)
+12 mg BID (QTY #14)
48 mg
Therapeutic dosing options range from 24 mg/day to 48 mg/day

Help your patients effectively reach a therapeutic dose with a 3-week prescription

  • Write your patients an initial script for AUSTEDO treatment through Week 3
  • Example of a patient reaching a 24 mg daily dose of AUSTEDO.1
  • OR provide a 2-week starter pack and prescribe 12 mg BID for Week 3*
    After effectively reaching a therapeutic dose1:
  • Evaluate tolerability and TD symptom improvement. Daily dose may be increased by 6 mg each week depending on patient’s response
  • Maintain effect dose once reached. AUSTEDO can be adjusted as needed over time

*Notify pharmacy if patient has been sampled.

Help your patients effectively reach a therapeutic dose with a 3-week prescription

  • Write your patients an initial script for AUSTEDO treatment through Week 3
  • OR provide a 2-week starter pack and prescribe 12 mg BID for Week 3*
    After effectively reaching a therapeutic dose1:
  • Evaluate tolerability and TD symptom improvement. Daily dose may be increased by 6 mg each week depending on patient’s response
  • Maintain effect dose once reached. AUSTEDO can be adjusted as needed over time

*Notify pharmacy if patient has been sampled.Example of a patient reaching a 24 mg daily dose of AUSTEDO.1

  • The recommended starting dose of AUSTEDO for patients with TD is 12 mg/day (6 mg twice daily)1
  • The dose of AUSTEDO may be increased at weekly intervals by 6 mg/day increments based on reduction of TD and tolerability1
  • Administer total daily dosages of 12 mg or above in 2 divided doses1
  • The maximum recommended daily dosage of AUSTEDO is 48 mg (24 mg twice daily)1
  • In patients who are poor CYP2D6 metabolizers or who are receiving strong CYP2D6 inhibitors, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg)1
  • For patients requiring AUSTEDO doses greater than 24 mg per day who are using AUSTEDO with other drugs known to prolong corrected QT (QTc), assess the QTc interval before and after increasing the dose of AUSTEDO or the other drugs1
  • Administer AUSTEDO with food1
  • Swallow AUSTEDO whole. Do not chew, crush, or break tablets1
If you'd like to be connected with a local AUSTEDO Sales Representative, please call 1-888-838-2872, Option #3, then Option #5.
Learn more about why AUSTEDO may be right for the diverse treatment needs of your patients.
REGISTER FOR UPDATES

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

Reference: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238. doi:10.2147/DDDT.S133205 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.